drugset / Trial / NCT00362414
Beta-hCG + Erythropoietin in Acute Stroke
Phase 2
Completed
15 enrolled
University of California, Irvine
Hoag Memorial Hospital Presbyterian · collabStem Cell Therapeutics Corp. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety of Beta-hCG + Erythropoietin in patients with acute ischemic stroke.
Timeline
- Start
- 2006-08
- Primary completion
- 2008-03
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Beta-hCG | Unknown | 10000 iu | Intramuscular |
| Subject | epoetin alfa | Protein / enzyme biologic | 30000 iu | Intravenous |